CVKD
Cadrenal Therapeutics, Inc.
0.9402$
-3.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | +50.2% | -75.0% | +214.2% | +0.0% | +0.0% | +0.0% | -21.3% | -13.4% | +162.2% | +417.1% | -92.7% | +0.0% | +38.4% | +0.0% | – | – | |
| – | – | – | – | – | – | – | – | -127.5% | – | – | – | -617.1% | – | – | – | – | – | – | |
| – | +1,032.3% | -72.1% | +106.4% | +2,680.0% | -92.6% | +1.2% | +48.0% | +74.2% | +99.3% | -37.4% | +96.0% | +8.5% | -35.4% | -36.1% | -3.2% | +15.8% | -8.6% | – | |
| – | +83.5% | +227.0% | +47.3% | -28.5% | -18.7% | +14.5% | +0.5% | +24.8% | +7.7% | +38.1% | +63.6% | -17.7% | +17.8% | -23.0% | +17.3% | -27.3% | +51.2% | – | |
| – | +182.9% | +101.7% | +10.5% | +290.6% | -75.6% | +11.4% | +10.6% | +38.9% | +40.5% | -0.3% | +73.9% | -8.3% | -4.8% | -26.8% | +12.1% | -18.0% | +32.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +221.9% | +116.8% | +74.1% | -69.3% | -100.0% | – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4,735.6% | – | -207.2% | – | -97.6% | +358.0% | -100.0% | +0.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.